Literature DB >> 10570053

Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate.

V Gorboulev1, C Volk, P Arndt, A Akhoundova, H Koepsell.   

Abstract

After site-directed mutagenesis, the organic cation transporter rOCT1 was expressed in Xenopus laevis oocytes or human embryonic kidney cells and functionally characterized. rOCT1 belongs to a new family of polyspecific transporters that includes transporters for organic cations and anions and the Na(+)-carnitine cotransporter. When glutamate was substituted for Asp475 (middle of the proposed 11th transmembrane alpha-helix), the V(max) values for choline, tetraethylammonium (TEA), N(1)-methylnicotinamide, and 1-methyl-4-phenylpyridinium were reduced by 89 to 98%. The apparent K(m) values were also decreased (choline by 15-fold, TEA by 8-fold, N(1)-methylnicotinamide by 4-fold) or remained constant (1-methyl-4-phenylpyridinium). After the mutation, the membrane potential dependence of the K(m) value for [(3)H]choline uptake was abolished. The affinity of n-tetraalkyl ammonium compounds to inhibit TEA uptake was increased. This affinity and its increase by the D475E mutation were increased with the length of the n-alkyl chains. After expression in X. laevis oocytes, the IC(50) ratios of wild-type and D475E mutant were 1.7 (tetramethylammonium), 4.3 (TEA), 5.0 (tetrapropylammonium), 5.0 (tetrabutylammonium), and 65 (tetrapentylammonium). Cationic inhibitors with ring structures were differentially affected: the IC(50) value for TEA inhibition by cyanine 863 remained unchanged, whereas it was increased for quinine. The data suggest that rOCT1 contains a large cation-binding pocket with several interaction domains that may be responsible for high-affinity binding of structurally different cations and that Asp475 is located close to one of these interaction domains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570053     DOI: 10.1124/mol.56.6.1254

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

Review 1.  Regulation of organic cation transport.

Authors:  Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Pflugers Arch       Date:  2004-11-16       Impact factor: 3.657

2.  Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.

Authors:  Philip J Sandoval; Kimberley M Zorn; Alex M Clark; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2018-06-08       Impact factor: 4.436

3.  Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.

Authors:  David J Wagner; Jennifer E Sager; Haichuan Duan; Nina Isoherranen; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2017-04-20       Impact factor: 3.922

4.  A substrate binding hinge domain is critical for transport-related structural changes of organic cation transporter 1.

Authors:  Brigitte Egenberger; Valentin Gorboulev; Thorsten Keller; Dmitry Gorbunov; Neha Gottlieb; Dietmar Geiger; Thomas D Mueller; Hermann Koepsell
Journal:  J Biol Chem       Date:  2012-07-18       Impact factor: 5.157

Review 5.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

6.  Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Biochem Pharmacol       Date:  2018-08-20       Impact factor: 5.858

7.  Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.

Authors:  Jaclyn N Harper; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

8.  Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.

Authors:  Monica Sala-Rabanal; Dan C Li; Gregory R Dake; Harley T Kurata; Mikhail Inyushin; Serguei N Skatchkov; Colin G Nichols
Journal:  Mol Pharm       Date:  2013-03-19       Impact factor: 4.939

9.  Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.

Authors:  Mathew Belzer; Mark Morales; Bhumasamudram Jagadish; Eugene A Mash; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2013-05-24       Impact factor: 4.030

Review 10.  The SLC22 drug transporter family.

Authors:  Hermann Koepsell; Hitoshi Endou
Journal:  Pflugers Arch       Date:  2003-07-19       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.